Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil
Objective: To evaluate the genetic tests is fundamental for the adequate treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI). Given that access to this evaluation is still limited for those who depend on the Brazilian Public Health System, it seems import...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2019-01-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20190004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849700340498169856 |
|---|---|
| author | Thais Abreu Almeida Jeanine Marie Nardin Amanda Jurgensen Janaina Takahashi Juliana Jung Graziele Losso José C. Casali-da-Rocha |
| author_facet | Thais Abreu Almeida Jeanine Marie Nardin Amanda Jurgensen Janaina Takahashi Juliana Jung Graziele Losso José C. Casali-da-Rocha |
| author_sort | Thais Abreu Almeida |
| collection | DOAJ |
| description |
Objective: To evaluate the genetic tests is fundamental for the adequate treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI). Given that access to this evaluation is still limited for those who depend on the Brazilian Public Health System, it seems important to provide regulatory agencies with epidemiological and prognostic information to guide future health policies and guidelines in Brazil. This work aims to characterize EGFR and KRAS mutations in NSCLC and associating them with patients demographic and tumor clinical-pathologic features. Methods: From 2004 to 2017, 237 metastatic NSCLC patients treated at Erasto Gäertner Cancer Hospital were included in this study. Electronic medical records were retrospectively reviewed and the mutational status EGFR and KRAS were defined. Results: We detected EGFR mutation in 20 samples (15.7%), and KRAS mutation in 26 samples (21.5%). The majority of EGFR mutations was detected within the exon 19 (n=9, 45.0%), and for KRAS G12V (n=8, 30.8%) and G12C (n=8, 30.8%) were the hotspots. The median overall survival was 11 months. We did not detect any statistical differences in survival rates between mutated and wild-type tumors neither for EGFR (p=0.898) nor for KRAS (p=0.458). Only two patients had access to TKI and were considered outliers with the best survival rates. Conclusion: We described important information about NSCLC biological behavior in a population treated in a reference public cancer center in South Brazil. Studies like this highlight the magnitude that TKI treatment could have in the overall survival of patients with NSCLC after being introduced into the SUS. Future studies that address the economic impact of this issue are also needed. Here we also make a comparison of our results with other regions of Brazil that have different genetic backgrounds to evaluate the impact of targeted therapies. |
| format | Article |
| id | doaj-art-694d5dfafcf04b40a9cd9cf558969035 |
| institution | DOAJ |
| issn | 2526-8732 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-694d5dfafcf04b40a9cd9cf5589690352025-08-20T03:18:19ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322019-01-011510.5935/2526-8732.20190004Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in BrazilThais Abreu Almeida0Jeanine Marie Nardin1Amanda Jurgensen2Janaina Takahashi3Juliana Jung4Graziele Losso5José C. Casali-da-Rocha6Hospital Erasto Gaertner. Rua: Dr. Ovande do AmaralHospital Erasto Gaertner, Departamento de Oncologia Clínica - Curitiba - Paraná - BrazilFaculdade Evangélica do Paraná, Curso de Graduação em Medicina - Curitiba - Paraná - BrazilFaculdade Evangélica do Paraná, Curso de Graduação em Medicina - Curitiba - Paraná - BrazilHospital Erasto Gaertner, Departamento de Oncologia Clínica - Curitiba - Paraná - BrazilLaboratorio Mantis Diagnosticos Avançados, Departamento de Biologia Molecular - Curitiba - Paraná - BrazilHospital Erasto Gaertner, Departamento de Oncologia Clínica - Curitiba - Paraná - Brazil Objective: To evaluate the genetic tests is fundamental for the adequate treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI). Given that access to this evaluation is still limited for those who depend on the Brazilian Public Health System, it seems important to provide regulatory agencies with epidemiological and prognostic information to guide future health policies and guidelines in Brazil. This work aims to characterize EGFR and KRAS mutations in NSCLC and associating them with patients demographic and tumor clinical-pathologic features. Methods: From 2004 to 2017, 237 metastatic NSCLC patients treated at Erasto Gäertner Cancer Hospital were included in this study. Electronic medical records were retrospectively reviewed and the mutational status EGFR and KRAS were defined. Results: We detected EGFR mutation in 20 samples (15.7%), and KRAS mutation in 26 samples (21.5%). The majority of EGFR mutations was detected within the exon 19 (n=9, 45.0%), and for KRAS G12V (n=8, 30.8%) and G12C (n=8, 30.8%) were the hotspots. The median overall survival was 11 months. We did not detect any statistical differences in survival rates between mutated and wild-type tumors neither for EGFR (p=0.898) nor for KRAS (p=0.458). Only two patients had access to TKI and were considered outliers with the best survival rates. Conclusion: We described important information about NSCLC biological behavior in a population treated in a reference public cancer center in South Brazil. Studies like this highlight the magnitude that TKI treatment could have in the overall survival of patients with NSCLC after being introduced into the SUS. Future studies that address the economic impact of this issue are also needed. Here we also make a comparison of our results with other regions of Brazil that have different genetic backgrounds to evaluate the impact of targeted therapies.http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20190004Lung NeoplasmsGeneserbB-1Kirsten murine sarcoma virusPublic HealthBrazil.Neoplasias PulmonaresGeneserbB-1Vírus do sarcoma murino de KirstenSaúde públicaBrasil. |
| spellingShingle | Thais Abreu Almeida Jeanine Marie Nardin Amanda Jurgensen Janaina Takahashi Juliana Jung Graziele Losso José C. Casali-da-Rocha Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil Brazilian Journal of Oncology Lung Neoplasms Genes erbB-1 Kirsten murine sarcoma virus Public Health Brazil. Neoplasias Pulmonares Genes erbB-1 Vírus do sarcoma murino de Kirsten Saúde pública Brasil. |
| title | Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil |
| title_full | Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil |
| title_fullStr | Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil |
| title_full_unstemmed | Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil |
| title_short | Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil |
| title_sort | prognostic impact of i egfr i and i kras i mutations in lung cancer survival during pre tki era the real scenario at a cancer public center of reference in brazil |
| topic | Lung Neoplasms Genes erbB-1 Kirsten murine sarcoma virus Public Health Brazil. Neoplasias Pulmonares Genes erbB-1 Vírus do sarcoma murino de Kirsten Saúde pública Brasil. |
| url | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20190004 |
| work_keys_str_mv | AT thaisabreualmeida prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil AT jeaninemarienardin prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil AT amandajurgensen prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil AT janainatakahashi prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil AT julianajung prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil AT grazielelosso prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil AT joseccasalidarocha prognosticimpactofiegfriandikrasimutationsinlungcancersurvivalduringpretkieratherealscenarioatacancerpubliccenterofreferenceinbrazil |